Tesamorelin + Ipamorelin Blend 10mg / 3mg

Tesamorelin 10 mg + Ipamorelin 3 mg is a dual-peptide research preparation supplied by Grail Formula for scientific investigation and controlled laboratory experimentation involving peptide-receptor interactions, growth hormone-associated signalling pathways, molecular endocrinology and experimental peptide biochemistry.

This research blend contains two structurally distinct synthetic peptides: Tesamorelin, a growth hormone-releasing hormone (GHRH) analogue, and Ipamorelin, a synthetic growth hormone secretagogue receptor (GHSR) agonist investigated in experimental receptor-signalling systems.

Supplied as a nominal 13 mg combined peptide preparation, the blend is accompanied by independent batch-specific analytical documentation from Liquilabs s.r.o., Czechia.

For research use only — not for human or veterinary use.

 

Product Overview

Tesamorelin 10 mg + Ipamorelin 3 mg combines two peptide research compounds associated with different molecular recognition systems investigated in experimental endocrinology.

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone, a peptide involved in the regulation of growth hormone-associated signalling through the GHRH receptor.

Ipamorelin is a synthetic pentapeptide investigated for its interaction with the growth hormone secretagogue receptor, commonly designated GHSR1a.

The two compounds provide a research context for investigating distinct receptor-associated signalling mechanisms, ligand-receptor interactions and biochemical pathways relevant to growth hormone regulatory biology.

Grail Formula supplies this preparation as a nominal 10 mg Tesamorelin and 3 mg Ipamorelin blend for controlled laboratory and in vitro research.

Independent third-party analysis was performed by Liquilabs s.r.o., Czechia. The Certificate of Analysis was published on 11 October 2026 and identifies batch GF-TESAIPA10/3-B243, laboratory sample LYO-1002.

The laboratory reported a measured Tesamorelin assay content of 10.17 mg ± 0.05 mg and an Ipamorelin assay content of 3.50 mg ± 0.02 mg.

Chromatographic purity was reported separately for each peptide: 99.1 % ± 0.5 percentage points for Tesamorelin and greater than 99.8 % for Ipamorelin.

The combined measured peptide assay content is 13.67 mg against the nominal total of 13 mg. This calculated total represents the sum of the two separately reported assay measurements.

The Certificate of Analysis also includes peptide-specific retention time identification and molecular ion mass determination, together with microbiological testing, bacterial endotoxin assessment and screening for seven elemental impurities.

These results document the analytical characteristics of the tested research preparation and do not independently establish receptor activity, biological potency, functional interactions between the peptides or suitability for administration.

 

Peptide Overview

Tesamorelin: GHRH analogue research

Tesamorelin is a synthetic peptide analogue of growth hormone-releasing hormone, a regulatory peptide investigated in molecular endocrinology and receptor-mediated signalling research.

GHRH-associated signalling involves interaction with the growth hormone-releasing hormone receptor, a G protein-coupled receptor involved in intracellular signal transduction.

Experimental research involving GHRH analogues examines receptor recognition, ligand binding, intracellular cyclic adenosine monophosphate (cAMP) signalling and downstream biochemical responses.

Tesamorelin is structurally related to the 44-amino-acid GHRH peptide and includes a chemical modification associated with its synthetic analogue structure.

This makes it relevant to research examining how modifications to peptide sequences and terminal structures may influence molecular recognition and experimental peptide stability.

The Liquilabs Certificate of Analysis reports a molecular ion mass identification result of 5135 Da ± 1 Da for Tesamorelin.

Ipamorelin: growth hormone secretagogue receptor research

Ipamorelin is a synthetic pentapeptide investigated as a ligand of the growth hormone secretagogue receptor, a G protein-coupled receptor associated with ghrelin-related signalling.

Unlike Tesamorelin, which is associated with GHRH receptor biology, Ipamorelin is investigated within the growth hormone secretagogue receptor signalling system.

Experimental studies involving GHSR ligands examine receptor binding, intracellular calcium-associated signalling, G protein activation and downstream molecular responses.

Ipamorelin is of scientific interest in comparative peptide pharmacology because its molecular structure differs considerably from larger GHRH analogues.

Its relatively short peptide structure also provides a research context for studying peptide-receptor recognition, synthetic peptide characterisation and structure-activity relationships.

The Liquilabs Certificate of Analysis reports a molecular ion mass identification result of 711 Da ± 1 Da for Ipamorelin.

Scientific context of the dual-peptide preparation

The combination of Tesamorelin and Ipamorelin provides a laboratory research material containing two distinct peptide structures associated with different receptor systems.

This distinction is relevant to experimental investigations examining peptide composition, analytical separation and receptor-associated molecular mechanisms.

However, the presence of both peptides in one preparation does not establish synergistic activity, enhanced receptor responses or any particular biological interaction.

Such properties would require dedicated experimental studies and are not evaluated in the supplied Certificate of Analysis.

 

Historical Background and Scientific Context

Scientific research into growth hormone regulatory biology developed through investigations of peptide signalling, endocrine regulation and the molecular mechanisms controlling receptor-mediated biochemical responses.

The identification and characterisation of growth hormone-releasing hormone provided researchers with an important molecular model for understanding peptide-associated endocrine signalling.

Advances in peptide synthesis subsequently enabled the development of synthetic GHRH analogues with modified molecular structures.

These compounds became subjects of research involving receptor recognition, peptide stability and intracellular signal transduction.

Tesamorelin emerged from this broader field of GHRH analogue development and has been investigated in biochemical, cellular and pharmacological research.

Its molecular characteristics make it relevant to experimental investigations involving GHRH receptor-associated pathways and peptide structure-function relationships.

In parallel, scientific research identified a separate family of synthetic compounds known as growth hormone secretagogues.

These compounds contributed to investigations into receptor-mediated signalling pathways distinct from those associated with GHRH.

The identification of the growth hormone secretagogue receptor provided an important molecular target for studying ligand recognition and intracellular signalling.

Subsequent research connected GHSR biology with the endogenous peptide ghrelin and expanded scientific understanding of this receptor system.

Ipamorelin was developed within the field of synthetic growth hormone secretagogue research and became a subject of experimental investigations involving receptor-associated peptide activity.

Its pentapeptide structure distinguishes it from larger regulatory peptides and provides a model for investigating relationships between molecular size, amino acid composition and receptor recognition.

Modern peptide research increasingly uses comparative molecular approaches to investigate how different peptide ligands interact with distinct receptor systems.

In analytical chemistry, the development of high-performance and ultra-high-performance liquid chromatography has enabled researchers to separate and quantify peptide components within complex preparations.

Mass spectrometry has further improved molecular identification by allowing peptide-associated ions to be characterised through mass-to-charge measurements and molecular mass evaluation.

For multi-peptide preparations, individual component analysis is particularly important because each peptide may have a different chromatographic purity, assay quantity and molecular identity profile.

The Tesamorelin 10 mg + Ipamorelin 3 mg blend can therefore be considered within the broader scientific context of synthetic peptide research, receptor-associated molecular biology and analytical characterisation of multi-component laboratory materials.

 

Mechanistic Focus in Research

The primary mechanistic research interest surrounding Tesamorelin and Ipamorelin concerns two distinct receptor-associated signalling systems investigated in molecular endocrinology.

GHRH receptor-associated signalling

Tesamorelin is investigated in relation to the growth hormone-releasing hormone receptor, a G protein-coupled receptor involved in peptide-associated intracellular signalling.

GHRH receptor activation is associated with intracellular pathways involving adenylate cyclase, cyclic AMP and protein kinase A-related signalling mechanisms.

Experimental research may examine receptor binding, intracellular second-messenger generation and molecular responses associated with GHRH receptor activity.

These investigations contribute to understanding peptide-receptor recognition and the biochemical characteristics of GHRH analogue signalling.

Growth hormone secretagogue receptor signalling

Ipamorelin is investigated as a synthetic peptide ligand associated with the growth hormone secretagogue receptor.

GHSR-related signalling is commonly studied in connection with G protein-coupled receptor activation and intracellular calcium-associated pathways.

Laboratory investigations may examine ligand binding, receptor activation, second-messenger signalling and the relationship between peptide structure and receptor-associated responses.

The precise characteristics of these responses depend on the experimental model, receptor expression and analytical methods employed.

Comparative receptor biology

Because Tesamorelin and Ipamorelin are associated with different receptor systems, they provide a scientific context for examining differences between peptide-receptor recognition mechanisms.

Comparative research may involve studies of receptor selectivity, molecular signalling intermediates and the structural characteristics of peptide ligands.

Such investigations require dedicated biological assays and cannot be established through chemical identity or chromatographic purity testing alone.

Intracellular second-messenger systems

G protein-coupled receptors participate in intracellular signalling through pathways involving second messengers, protein kinases and other regulatory molecules.

GHRH receptor-associated signalling is commonly investigated in relation to cAMP-dependent pathways, while GHSR-associated signalling is frequently examined through calcium-related mechanisms.

These distinctions are relevant to molecular biology research examining the organisation and regulation of intracellular signalling networks.

Peptide structure and molecular recognition

The substantial structural difference between Tesamorelin and Ipamorelin provides a research context for studying relationships between peptide size, amino acid sequence and receptor-associated molecular recognition.

Tesamorelin is a larger GHRH analogue, while Ipamorelin is a comparatively short synthetic pentapeptide.

Researchers may examine these structural differences using analytical chemistry, molecular modelling and validated biochemical assays.

Multi-component peptide analysis

Laboratory research involving peptide blends requires methods capable of distinguishing individual components and evaluating their respective quantities.

Chromatographic separation and mass spectrometric identification provide analytical tools for investigating multi-peptide preparations.

In the supplied Liquilabs report, Tesamorelin and Ipamorelin were assessed separately for assay content, chromatographic purity, retention time identification and molecular ion mass.

The report does not contain receptor activation measurements, growth hormone secretion assays, comparative signalling experiments or studies establishing functional interactions between the two peptides.

Accordingly, the mechanistic research areas described above represent scientific context rather than experimentally confirmed biological activity of batch GF-TESAIPA10/3-B243.

 

Analytical Verification (COA)

Grail Formula provides independent batch-specific analytical documentation through testing conducted by Liquilabs s.r.o., Czechia.

The Certificate of Analysis for Tesamorelin 10 mg + Ipamorelin 3 mg was published on 11 October 2026 and identifies batch GF-TESAIPA10/3-B243, laboratory sample LYO-1002.

The 18-page report includes separate peptide assay measurements, chromatographic purity results, retention time identification, mass spectrometry, bacterial endotoxin testing, microbiological counts and elemental impurity screening.

Tesamorelin assay and purity

• Nominal Tesamorelin quantity: 10 mg
• Measured Tesamorelin assay content: 10.17 mg ± 0.05 mg
• Reported Tesamorelin chromatographic purity: 99.1 % ± 0.5 percentage points
• Measured difference from nominal Tesamorelin quantity: 0.17 mg above 10 mg
• Measured Tesamorelin assay as a proportion of nominal quantity: 101.7 %

The Tesamorelin assay content exceeds the nominal quantity by 1.7 %. This positive difference is disclosed separately from the chromatographic purity result.

Ipamorelin assay and purity

• Nominal Ipamorelin quantity: 3 mg
• Measured Ipamorelin assay content: 3.50 mg ± 0.02 mg
• Reported Ipamorelin chromatographic purity: greater than 99.8 %
• Measured difference from nominal Ipamorelin quantity: 0.50 mg above 3 mg
• Measured Ipamorelin assay as a proportion of nominal quantity: approximately 116.7 %

The Ipamorelin assay content exceeds the nominal quantity by approximately 16.7 %. This difference is particularly relevant when interpreting the batch-specific analytical results.

The chromatographic purity of greater than 99.8 % does not indicate that the nominal 3 mg quantity was recovered. Purity and assay content are separate analytical measurements.

Combined peptide content

• Nominal combined peptide quantity: 13 mg
• Calculated combined measured assay content: 13.67 mg
• Calculated positive difference from nominal combined quantity: 0.67 mg
• Calculated combined assay as a proportion of nominal total: approximately 105.15 %

The combined values are calculated from the two separately reported peptide assay measurements. They are not presented as an additional independent laboratory assay.

Peptide identity assessment

• Ipamorelin retention time identification result: 0.996 ± 0.005
• Tesamorelin retention time identification result: 0.998 ± 0.005
• Ipamorelin molecular ion mass identification: 711 Da ± 1 Da
• Tesamorelin molecular ion mass identification: 5135 Da ± 1 Da
• Analytical screening designation: Peptide Screening 0.1% TFA

The report includes chromatographic and mass spectrometric documentation supporting the analytical characterisation of the two peptide components.

The retention time values are reproduced as reported. The summary does not provide separate explicit pass/fail interpretations for these measurements.

No individual FTIR spectrum identification results are listed for Tesamorelin or Ipamorelin in the supplied Certificate of Analysis.

Bacterial endotoxin assessment

• Bacterial endotoxin: 0.007 EU/mg
• Reported uncertainty: ± 0 EU/mg
• Laboratory acceptable range: 0–0.5 EU/mg
• Analytical reference: USP <85> / European Pharmacopoeia 2.6.14
• Method: Chromogenic bacterial endotoxin testing

The reported bacterial endotoxin concentration of 0.007 EU/mg falls within the laboratory’s stated acceptable range.

This measurement applies to the tested blend sample and is not presented as a separate endotoxin result for each peptide.

The result does not establish sterility, biological safety or suitability for administration.

Microbiological assessment

• Total aerobic microbial count: 0 CFU/g
• Total yeast and mould count: 0 CFU/g
• Reported aerobic microbial count range: 0–1000 CFU/g
• Reported yeast and mould count range: 0–100 CFU/g
• Analytical reference: USP <61> / European Pharmacopoeia 2.6.12
• Method: Plate-count testing

Both microbiological counts were reported as zero under the applied laboratory testing conditions.

These findings describe the tested blend sample and do not establish the absence of every possible microorganism.

Elemental impurity screening

Seven elemental impurities were evaluated using procedures referenced to USP <232> and European Pharmacopoeia 5.20 / 2.4.20.

• Arsenic: below 0.001 ppm
• Cadmium: below 0.001 ppm
• Mercury (listed as quicksilver): below 0.001 ppm
• Lead: below 0.001 ppm
• Nickel: below 0.001 ppm
• Vanadium: below 0.001 ppm
• Cobalt: below 0.001 ppm

All seven reported elemental impurity concentrations were below 0.001 ppm and within their respective laboratory acceptable ranges.

These results describe the tested blend sample rather than separate elemental impurity profiles for each individual peptide.

The complete 18-page Certificate of Analysis includes method specifications, calibration information, chromatographic records, mass spectrometric documentation, endotoxin determination and microbiological testing methodology.

 

Research Applications

Tesamorelin and Ipamorelin are investigated in experimental molecular endocrinology, peptide-receptor biology and laboratory research involving growth hormone-associated regulatory pathways.

Their different molecular structures and receptor associations provide a scientific context for investigating distinct peptide signalling systems.

Potential areas of laboratory investigation include:

• Growth hormone-releasing hormone receptor research
• Growth hormone secretagogue receptor investigations
• Experimental G protein-coupled receptor signalling
• Peptide ligand-receptor interaction studies
• cAMP-associated intracellular signalling research
• Calcium-associated receptor signalling investigations
• Comparative peptide structure-activity research
• Experimental molecular endocrinology
• Multi-peptide chromatographic separation and quantification
• Mass spectrometric peptide identity assessment
• Analytical characterisation of dual-peptide research preparations

These applications describe scientific research directions rather than verified biological activity of the tested batch.

Any investigation of functional interactions between Tesamorelin and Ipamorelin requires dedicated experimental testing and cannot be inferred from the presence of both peptides in one preparation.

Batch-specific analytical documentation can support laboratory recordkeeping and provide researchers with information about the measured chemical characteristics of the preparation.

 

Grail Formula Quality

Grail Formula focuses on supplying laboratory research compounds supported by transparent product information and independent analytical documentation.

For Tesamorelin 10 mg + Ipamorelin 3 mg, Liquilabs testing provides separate measurements of peptide assay content, chromatographic purity, retention time identification and molecular ion mass for each component.

The report also documents bacterial endotoxin concentration, microbiological counts and elemental impurity screening for the tested blend.

Individual component analysis is particularly important for multi-peptide research preparations because the measured quantities and chromatographic purity values may differ between peptides.

The reported Ipamorelin assay content of 3.50 mg against the nominal 3 mg quantity is disclosed transparently rather than being obscured by the high chromatographic purity result.

Each analytical result should be interpreted within the scope of the tested sample, the applied laboratory methodology and the reported measurement uncertainty.

 

When You Choose Grail Formula

Grail Formula provides Tesamorelin 10 mg + Ipamorelin 3 mg with independent batch-specific analytical documentation from Liquilabs s.r.o., Czechia.

Researchers can examine the separate assay, purity, retention time and molecular ion mass results for Tesamorelin and Ipamorelin, together with the microbiological and elemental impurity findings for the blend.

The Certificate of Analysis identifies the production batch, laboratory sample and publication date, supporting analytical traceability and laboratory documentation.

Grail Formula emphasises factual scientific descriptions, transparent reporting and clear distinctions between analytical measurements and biological properties that have not been established.

This approach supports responsible documentation of research materials used in controlled laboratory investigations involving peptide biochemistry and receptor-associated molecular signalling.

 

Research Use Limitation

• Used solely for laboratory and in vitro research
• Not approved for human consumption
• Not approved for veterinary use
• Not intended for diagnostic purposes
• Not intended for therapeutic applications
• Not permitted for clinical administration
• For research use only

• Independently analysed by Liquilabs s.r.o. Czechia
• Dual-peptide research preparation containing nominal 10 mg Tesamorelin and 3 mg Ipamorelin
• Tesamorelin chromatographic purity: 99.1 % ± 0.5 percentage points
• Ipamorelin chromatographic purity: greater than 99.8 %
• Tesamorelin assay content measured at 10.17 mg ± 0.05 mg
• Ipamorelin assay content measured at 3.50 mg ± 0.02 mg
• Tesamorelin assay content 1.7 % above nominal quantity
• Ipamorelin assay content approximately 16.7 % above nominal quantity
• Calculated combined measured peptide content: 13.67 mg against nominal 13 mg
• Individual peptide identification evaluated by retention time analysis
• Tesamorelin retention time identification: 0.998 ± 0.005
• Ipamorelin retention time identification: 0.996 ± 0.005
• Tesamorelin molecular ion mass: 5135 Da ± 1 Da
• Ipamorelin molecular ion mass: 711 Da ± 1 Da
• Bacterial endotoxin level of 0.007 EU/mg
• Total aerobic microbial count: 0 CFU/g
• Total yeast and mould count: 0 CFU/g
• All seven reported elemental impurities below 0.001 ppm
• Batch number: GF-TESAIPA10/3-B243
• Laboratory sample identification: LYO-1002
• COA publication date: 11 October 2026
• Independent 18-page batch-specific Certificate of Analysis
• Research compounds associated with GHRH and GHSR receptor signalling investigations
• For research use only – not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.